



HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration No. 201735688C)
(Incorporated in the Republic of Singapore)

ENTRY INTO MEMORANDUM OF UNDERSTANDING WITH DOCTOR ANYWHERE

The Board of Directors of Hyphens Pharma International Limited (the “Company”) wishes to announce that the Company’s wholly-owned subsidiary company, Pan-Malayan Pharmaceuticals Pte Ltd (“PMP”), has entered into a non-binding memorandum of understanding (the “MOU”) with Doctor Anywhere Operations Pte. Ltd. (“DAO”) on 5 December 2018.

DAO is a healthtech company founded to improve healthcare delivery through innovation and technology. It is part of the Licensing Experimentation and Adaptation Programme for telemedicine under the Ministry of Health’s regulatory sandbox initiative.

Pursuant to the MOU, both parties intend to form a strategic partnership for PMP and/or its affiliate to, inter alia, supply pharmaceuticals and medical supplies to DAO’s telemedicine and/or their affiliated clinics.

The Group’s entry into the MOU is not expected to have a material impact on the earnings per share or net tangible assets per share of the Group for the current financial year ending 31 December 2018.

None of the directors or controlling shareholders of the Company has any interest, direct or indirect, in the MOU, PMP or DAO, save for their respective shareholdings in the Company (if any).

As the MOU is non-binding and may or may not lead to the entry into any formalised agreements, shareholders and potential investors are advised to exercise caution when trading in the Company’s shares. Shareholders should consult their financial, tax, legal or other professional advisers if they have any doubt about the actions that they should take.

The Company will make such further announcement(s) to keep shareholders informed, as and when there are material updates or developments in connection with the MOU.

BY ORDER OF THE BOARD

Lim See Wah

Chairman and Chief Executive Officer

5 December 2018

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Miss Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Vice President, who can be contacted at 12 Marina Boulevard Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone +65 6878 8888.